Organisation paid for research Program year 2025 Source: CMS Open Payments

Midwest Eye Institute

Neither a doctor nor a teaching hospital

Research payments

$5,113,504

39 payments

Through program year 2025, Midwest Eye Institute is reported as receiving $5,113,504 in research payments, across 39 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,885,184 3
2024 Research $1,214,408 1
2023 Research $186,034 9
2022 Research $152,040 8
2021 Research $392,350 7
2020 Research $83,458 3
2019 Research $200,029 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $5,040,210 29 payments
  2. AbbVie, Inc. $46,378 4 payments
  3. Allergan Inc. $26,916 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Participant and Investigator Masked, Placebo-Controlled, Multicenter, Proof-Of-Concept Study to Assess the Safety and Efficacy of Lnp023 (Iptacopan) in Patients With Early and Intermediate Age-Related MacUlar Degeneration $4,206,203 5 payments
  2. A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic MacUlar Edema $187,089 3 payments
  3. A 96-Week, Two-Arm, Randomized, Single-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 MG Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy $146,375 5 payments
  4. An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to MacUlar Edema Secondary to Branch Retinal Vein Occlusion (Raptor) $143,360 1 payment
  5. A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $109,621 5 payments
  6. A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due to MacUlar Edema (Me) Secondary to Central Retinal Vein Occlusion (Crvo) $84,478 6 payments
  7. ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study $80,006 1 payment
  8. A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $60,351 1 payment
  9. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $46,378 4 payments
  10. An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to MacUlar Edema Secondary to Branch Retinal Vein Occlusi $22,727 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record